Edition:
United Kingdom

Saumya Joseph

Amag's female libido injectable therapy to sell at $899

06 Aug 2019

Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for hypoactive sexual desire disorder (HSDD).

Amag's female libido injectable therapy to sell at $899

06 Aug 2019

Aug 6 Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for the condition.

Newer drugs help Eli Lilly top Wall Street quarterly profit estimate

30 Jul 2019

Eli Lilly and Co reported a second-quarter profit that topped Wall Street estimates and raised its 2019 earnings forecast on Tuesday, as higher demand for newer drugs offset increased discounts for the U.S. Medicare program and sales declines of medicines that lost patent protection.

Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal

29 Jul 2019

Exact Sciences Corp said on Monday it will buy peer Genomic Health Inc for about $2.8 billion (£2.27 billion) in cash and stock, expanding the cancer diagnostic company's testing capabilities to breast and prostate cancers.

Boston Scientific's narrow profit beat fails to excite investors

24 Jul 2019

Boston Scientific Corp narrowly beat Wall Street estimates for quarterly profit on Wednesday, helped by higher sales of its surgical products used to treat urological and pelvic conditions.

Multiple sclerosis drug helps Biogen beat Wall Street profit expectations

23 Jul 2019

Biogen Inc reported better-than-expected second quarter profit and raised its 2019 earnings forecast on Tuesday, driven by higher sales of its top-selling multiple sclerosis drug Tecfidera and lower taxes.

Abbott hits record high as diabetes device fuels profit beat

17 Jul 2019

Abbott Laboratories beat analysts' estimates for quarterly profit and lifted its full-year earnings forecast on Wednesday, boosted by a near 64% jump in sales of its blood sugar monitoring device.

Amneal cuts forecast as epinephrine shot supply issues linger, shares slump 36%

10 Jul 2019

Shares of Amneal Pharmaceuticals Inc plunged 36% to an all-time low on Wednesday after the generic drugmaker cut its 2019 core earnings forecast due to supply uncertainties related to its epinephrine auto-injectors.

World News